Diffuse large B cell lymphoma: Management of first relapse or primary refractory disease in transplant-eligible patients

This algorithm describes management for transplant-eligible patients with primary refractory DLBCL or first relapse. Many institutions limit transplantation to patients ≤75 years with adequate heart, kidney, and liver function and performance status. Refer to related UpToDate material for details of fitness for transplantation, diagnosis, treatment, and response assessment.

DLBCL: diffuse large B cell lymphoma; CAR-T cell: chimeric antigen receptor T cell; PET: positron emission tomography; HCT: hematopoietic cell transplantation; CR: complete response; PR: partial response.

* If CAR-T cell therapy is not available, autologous HCT is an acceptable, yet less effective option.

¶ Refer to related UpToDate material for descriptions of salvage chemotherapy regimens.

Δ Management of second or later relapse of DLBCL is addressed separately.

◊ UpToDate contributors differ in managing patients with PR after salvage therapy; either approach is considered acceptable.

Graphic 142186 Version 1.0

خرید پکیج

Diffuse large B cell lymphoma: Management of first relapse or primary refractory disease in transplant-eligible patients